MET-targeting antibody (emibetuzumab) and kinase inhibitor (merestinib) as single agent or in combination in a cancer model bearing MET exon 14 skipping

Purpose Approximately 3% of lung cancer bears mutations leading to MET exon 14 skipping, an oncogenic driver which is further evidenced by case reports of patient response to MET kinase inhibitor treatment. Approximately 15% of tumors harboring MET exon14 skipping have concurrent MET amplification....

Descripción completa

Detalles Bibliográficos
Autores principales: Yan, S. Betty, Um, Suzane L., Peek, Victoria L., Stephens, Jennifer R., Zeng, Wei, Konicek, Bruce W., Liu, Ling, Manro, Jason R., Wacheck, Volker, Walgren, Richard A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2017
Materias:
Preclinical Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6061111/
https://www.ncbi.nlm.nih.gov/pubmed/29188469
http://dx.doi.org/10.1007/s10637-017-0545-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6061111/
https://www.ncbi.nlm.nih.gov/pubmed/29188469
http://dx.doi.org/10.1007/s10637-017-0545-x

Ejemplares similares